Related Experiment Video
Updated: Jun 14, 2026
Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue
Published on: May 17, 2018
Cancer-related fatigue: determinants during neoadjuvant chemotherapy - prospective cohort study
Karen Abrahao1,2, Anke Bergmann3, Inês Mattos2
1Clinical Epidemiology Division, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil karen.abrahao@gmail.com.
Objectives:
Cancer-related fatigue (CRF) is one of the most prevalent and debilitating symptoms among women undergoing neoadjuvant chemotherapy for breast cancer. This study analysed fatigue trajectories and identified modifiable determinants of fatigue worsening.
Methods:
Prospective cohort of women with stage I-III breast cancer treated with neoadjuvant chemotherapy at a national cancer centre. Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue), clinical data, physical activity, handgrip strength, depressive symptoms, pain, insomnia and anaemia were assessed at baseline and across chemotherapy cycles. Generalised estimating equations modelled fatigue variation over time.
Results:
Fatigue remained stable after anthracyclines but worsened significantly during the taxane phase. Independent determinants of greater fatigue worsening included overweight/obesity, insomnia, depressive symptoms, pain, anaemia and lower handgrip strength. Moderate-to-vigorous physical activity was protective.
Conclusions:
Several modifiable factors contributed to CRF worsening during neoadjuvant treatment. Early identification and management of these conditions may mitigate fatigue progression and improve quality of life and treatment tolerance.
Related Concept Videos
01:21Cancer Survival Analysis
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers